APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Analysis and Forecast 2026-2032

19 December 2025194 pages

Choose your research edition.

Industry ResearchVaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug include Novartis AG, Pfizer Inc, AstraZeneca Plc, Seattle Genetics Inc, NuvOx Pharma LLC, Modus Therapeutics Holding AB, Gilead Sciences Inc and Bristol-Myers Squibb Company, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug revenue, projected growth trends, production technology, application and end-user industry.

Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Company

Novartis AG

Pfizer Inc

AstraZeneca Plc

Seattle Genetics Inc

NuvOx Pharma LLC

Modus Therapeutics Holding AB

Gilead Sciences Inc

Bristol-Myers Squibb Company

Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Type

SGD-2083

Crizanlizumab

PF-04447943

NVX-508

Others

Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Application

Clinic

Hospital

Others

Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. SGD-2083 Major Player Table 3. Crizanlizumab Major Player Table 4. PF-04447943 Major Player Table 5. NVX-508 Major Player Table 6. Others Major Player Table 7. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Clinic Major Player Table 9. Hospital Major Player Table 10. Others Major Player Table 11. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Trends Table 12. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Drivers Table 13. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Opportunities and Challenges Table 14. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Restraints Table 15. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Region (2021-2026) Table 18. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Region (2027-2032) Table 20. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Players (2021-2026) Table 22. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Key Players Headquarters & Area Served Table 24. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players, Product Type & Application Table 25. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Type (2021-2026) Table 32. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Type (2027-2032) Table 33. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Application (2021-2026) Table 37. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Application (2027-2032) Table 38. Novartis AG Company Information Table 39. Novartis AG Business Overview Table 40. Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio Table 42. Novartis AG Recent Development Table 43. Pfizer Inc Company Information Table 44. Pfizer Inc Business Overview Table 45. Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio Table 47. Pfizer Inc Recent Development Table 48. AstraZeneca Plc Company Information Table 49. AstraZeneca Plc Business Overview Table 50. AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio Table 52. AstraZeneca Plc Recent Development Table 53. Seattle Genetics Inc Company Information Table 54. Seattle Genetics Inc Business Overview Table 55. Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio Table 57. Seattle Genetics Inc Recent Development Table 58. NuvOx Pharma LLC Company Information Table 59. NuvOx Pharma LLC Business Overview Table 60. NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio Table 62. NuvOx Pharma LLC Recent Development Table 63. Modus Therapeutics Holding AB Company Information Table 64. Modus Therapeutics Holding AB Business Overview Table 65. Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio Table 67. Modus Therapeutics Holding AB Recent Development Table 68. Gilead Sciences Inc Company Information Table 69. Gilead Sciences Inc Business Overview Table 70. Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio Table 72. Gilead Sciences Inc Recent Development Table 73. Bristol-Myers Squibb Company Company Information Table 74. Bristol-Myers Squibb Company Business Overview Table 75. Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio Table 77. Bristol-Myers Squibb Company Recent Development Table 78. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 79. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 80. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 81. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 82. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 83. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 84. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (US$ Million) & (2027-2032) Table 85. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 86. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 87. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 88. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 89. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 90. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 91. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (US$ Million) & (2027-2032) Table 92. China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 93. China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 94. China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 95. China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 96. Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 97. Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 98. Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 99. Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 100. Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 101. Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Region (US$ Million) & (2021-2026) Table 102. Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Region (US$ Million) & (2027-2032) Table 103. SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 104. SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 105. SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 106. SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 107. SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 109. SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (US$ Million) & (2027-2032) Table 110. Research Programs/Design for This Report Table 111. Authors List of This Report Table 112. Secondary Sources Table 113. Primary Sources List of Figures Figure 1. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Image Figure 2. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. SGD-2083 Image Figure 5. Crizanlizumab Image Figure 6. PF-04447943 Image Figure 7. NVX-508 Image Figure 8. Others Image Figure 9. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size Share 2021 VS 2025 VS 2032 Figure 11. Clinic Image Figure 12. Hospital Image Figure 13. Others Image Figure 14. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (US$ Million) & (2021-2032) Figure 15. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Type (2021-2032) Figure 22. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Application (2021-2032) Figure 25. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Type (2021-2032) Figure 27. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Application (2021-2032) Figure 28. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Country (2021-2032) Figure 29. United States Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Type (2021-2032) Figure 34. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Application (2021-2032) Figure 35. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Country (2021-2032) Figure 36. Germany Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Type (2021-2032) Figure 46. China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Application (2021-2032) Figure 47. Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Type (2021-2032) Figure 49. Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Application (2021-2032) Figure 50. Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Region (2021-2032) Figure 51. Japan Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Type (2021-2032) Figure 59. SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Application (2021-2032) Figure 60. SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Country (2021-2032) Figure 61. Brazil Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • SGD-2083
  • Crizanlizumab
  • PF-04447943
  • NVX-508
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Novartis AG
  • Pfizer Inc
  • AstraZeneca Plc
  • Seattle Genetics Inc
  • NuvOx Pharma LLC
  • Modus Therapeutics Holding AB
  • Gilead Sciences Inc
  • Bristol-Myers Squibb Company

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market by Type
  3. 1.2.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 SGD-2083
  5. 1.2.3 Crizanlizumab
  6. 1.2.4 PF-04447943
  7. 1.2.5 NVX-508
  8. 1.2.6 Others
  9. 1.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market by Application
  10. 1.3.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Clinic
  12. 1.3.3 Hospital
  13. 1.3.4 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Dynamics
  1. 2.1 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Trends
  2. 2.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Drivers
  3. 2.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Opportunities and Challenges
  4. 2.4 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Perspective (2021-2032)
  2. 3.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Growth Trends by Region
  3. 3.2.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Players
  2. 4.1.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Key Players Headquarters & Area Served
  7. 4.4 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players, Product Type & Application
  8. 4.5 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market CR5 and HHI
  11. 4.6.3 2025 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Tier 1, Tier 2, and Tier 3
5 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type
  1. 5.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021-2032)
  3. 5.3 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Type (2021-2032)
6 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application
  1. 6.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021-2032)
  3. 6.3 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis AG
  2. 7.1.1 Novartis AG Company Information
  3. 7.1.2 Novartis AG Business Overview
  4. 7.1.3 Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
  6. 7.1.5 Novartis AG Recent Developments
  7. 7.2 Pfizer Inc
  8. 7.2.1 Pfizer Inc Company Information
  9. 7.2.2 Pfizer Inc Business Overview
  10. 7.2.3 Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
  12. 7.2.5 Pfizer Inc Recent Developments
  13. 7.3 AstraZeneca Plc
  14. 7.3.1 AstraZeneca Plc Company Information
  15. 7.3.2 AstraZeneca Plc Business Overview
  16. 7.3.3 AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
  18. 7.3.5 AstraZeneca Plc Recent Developments
  19. 7.4 Seattle Genetics Inc
  20. 7.4.1 Seattle Genetics Inc Company Information
  21. 7.4.2 Seattle Genetics Inc Business Overview
  22. 7.4.3 Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
  24. 7.4.5 Seattle Genetics Inc Recent Developments
  25. 7.5 NuvOx Pharma LLC
  26. 7.5.1 NuvOx Pharma LLC Company Information
  27. 7.5.2 NuvOx Pharma LLC Business Overview
  28. 7.5.3 NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
  30. 7.5.5 NuvOx Pharma LLC Recent Developments
  31. 7.6 Modus Therapeutics Holding AB
  32. 7.6.1 Modus Therapeutics Holding AB Company Information
  33. 7.6.2 Modus Therapeutics Holding AB Business Overview
  34. 7.6.3 Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
  36. 7.6.5 Modus Therapeutics Holding AB Recent Developments
  37. 7.7 Gilead Sciences Inc
  38. 7.7.1 Gilead Sciences Inc Company Information
  39. 7.7.2 Gilead Sciences Inc Business Overview
  40. 7.7.3 Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
  42. 7.7.5 Gilead Sciences Inc Recent Developments
  43. 7.8 Bristol-Myers Squibb Company
  44. 7.8.1 Bristol-Myers Squibb Company Company Information
  45. 7.8.2 Bristol-Myers Squibb Company Business Overview
  46. 7.8.3 Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
  48. 7.8.5 Bristol-Myers Squibb Company Recent Developments
8 North America
  1. 8.1 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2021-2032)
  2. 8.2 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2027-2032)
  5. 8.3 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2027-2032)
  9. 8.5 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country
  11. 8.6.1 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2021-2032)
  2. 9.2 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country
  11. 9.6.1 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2021-2032)
  2. 10.2 China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2027-2032)
  5. 10.3 China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2027-2032)
  9. 10.5 China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2021-2032)
  2. 11.2 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country
  11. 11.6.1 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2021-2032)
  2. 12.2 SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country
  11. 12.6.1 SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst